[1] STRILCHUK L, FOGACCI F, CICERO AF.Safety and tolerability of available urate-lowering drugs: a critical review[J]. Expert Opinion on Drug Safety, 2019, 18(4): 261-271. [2] JI Y.Warning: Anti-gout drug benzbromarone can cause severe hepatitis[J]. Japanese Medical Bulletin(日本医学介绍), 2000, 21(6): 285. [3] None. Sanofi-Synthélabo has withdrawn its hyperuricaemic product, 'Desuric' [benzbromarone] in France[J]. Reactions Weekly, 2003, 952(1): 2. [4] National Medical Products Administration. Adverse drug reaction information bulletin (No.65) Be alert to the risk of liver damage of benzbromarone[EB/OL].(2014-12-31)[2021-08-18]. https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20141231120001298.html. [5] National Medical Products Administration.Announcement of NMPA on the revision of the instructions for the oral preparation of benzbromarone (No.150, 2020) [EB/OL].(2020-12-30)[2021-08-18]. https://www.nmpa.gov.cn/xxgk/ggtg/ypshmshxdgg/20201230172451118.html. [6] Chinese Society of Hepatology CMA. Guidelines for the diagnosis and treatment of drug-related liver injury[J]. Chinese Journal of Liver Diseases(中华肝脏病杂志), 2015, 23(11): 810-820. [7] KAUFMANN P, TRK M, HNNI A, et al.Mechanisms of benzarone and benzbromarone induced hepatic toxicity[J]. Hepatology, 2005, 41(4): 925-935. [8] FELSER A, LINDINGER PW, SCHNELL D, et al.Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure[J]. Toxicology, 2014, 324(10): 136-146. [9] GUENGERICH FP.A history of the roles of cytochrome P450 enzymes in the toxicity of drugs[J]. Toxicological Research, 2021, 37(1): 1-23. [10] JALADANKI CK, GAHLAWAT A, RATHOD G, et al.Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450[J]. Drug Metabolism Reviews, 2020, 52(3): 366-394. [11] KITAGAWARA Y, OHE T, TACHIBANA K, et al.Novel bioactivation pathway of benzbromarone mediated by cytochrome P450[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals, 2015, 43(9): 1303-1306. [12] MAHO S, SHUICHI S.Metabolic activation of hepatotoxic drug (benzbromarone) induced mitochondrial membrane permeability transition[J]. Toxicology & Applied Pharmacology, 2015, 288(1): 12-18. [13] CHO N, KOBAYASHI K, YOSHIDA M, et al.Identification of novel glutathione adducts of benzbromarone in human liver microsomes[J]. Drug Metabolism and Pharmacokinetics, 2016, 32(1): 46-52. [14] WANG H, FENG YK, WANG Q, et al.Cysteine-based protein adduction by epoxide-derived metabolite(s) of benzbromarone[J]. Chemical Research in Toxicology, 2016, 29(12): 2145-2152. [15] ROOS NJ, DUTHALER U, Bouitbir J, et al.The uricosuric benzbromarone disturbs the mitochondrial redox homeostasis and activates the NRF2 signaling pathway in HepG2 cells[J]. Free Radical Biology and Medicine, 2020, 152(7): 216-226. [16] SUN P, ZHU JJ, WANG T, et al.Benzbromarone aggravates hepatic steatosis in obese individuals[J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018, 1864(6): 2067-2077. [17] LEE MHH, GRAHAM GG, WILLIAMS KM, et al.A benefit-risk assessment of benzbromarone in the treatment of gout[J]. Drug Safety, 2008, 31(8): 643-665. [18] DK TK.Effects of long-term administration with generic benzbromarone on serum uric acid level and liver function in hyperuricemia patients[J]. Generic Research: Official Journal of the Japan Generic Pharmaceutical Society, 2011, 5(1): 22-26. [19] TORIi, Pharmaceutical, Co, et al. Post-marketing surveillance of benzbromarone (Urinorm® Tablets) - incidences of adverse drug reactions and changes in laboratory values relating to safety and efficacy under routine drug usage[J]. Gout & Nucleic Acid Metabolism, 2015, 35(1): 19-29. [20] STAMP LK, HASLETT J, FRAMPTON C, et al.The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand[J]. Internal Medicine Journal, 2016, 46(9): 1075-1080. [21] ZHENG JD, ZHUO SH, HONG HZ, et al.Analysis of the use of commonly used anti-gout drugs in a hospital from 2017 to 2019[J]. China Prescription Drugs(中国处方药), 2020, 18(7): 61-62. [22] GUAN HM.Analysis of the efficacy and safety of benzbromarone and allopurinol in reducing uric acid in patients with hyperuricemia and gout[J]. Electronic Journal of Clinical Medicine Literature(临床医药文献电子杂志), 2019, 6(51): 156-157. [23] LV Q, ZHANG H, QIAN CP, et al.Comparison of the efficacy of benzbromarone and febuxostat in the treatment of gout[J]. Chinese School Medicine(中国校医), 2020, 34(11): 863-865. [24] HONG Y, ZHANG Y.Comparison of the safety and efficacy of febuxostat, benzbromarone and allopurinol in the treatment of hyperuricemia[J]. Sichuan Journal of Anatomy(四川解剖学杂志), 2020, 28(1): 101-103. [25] XIE WQ, DIAO JH, WANG YL.Exploring the clinical effects of febuxostat and benzbromarone in the treatment of elderly patients with gout[J]. Medical Theory and Practice(医学理论与实践), 2020, 33(5): 761-762. [26] LU XJ, ZHOU ZA, SU S, et al.Effect of benzbromarone combined with glucocorticoid therapy on patients' clinical outcomes and AST ALT UA levels in patients with gouty arthritis[J]. Hebei Medicine(河北医学), 2021, 27(1): 125-128. [27] LI H.Clinical efficacy and safety analysis of benzbromarone in the treatment of hyperuricemia[J]. Continuing Medical Education in China(中国继续医学教育), 2017, 9(33): 86-87. [28] RICHETTE P, DOHERTY M, PASCUAL E, et al.2016 updated EULAR evidence-based recommendations for the management of gout[J]. Annals of the Rheumatic Diseases, 2017, 76(1): 29-42. [29] YAMANAKA H.Japanese guideline for the management of hyperuricemia and gout: second edition[J]. Nucleosides Nucleotides Nucleic Acids, 2011, 30(12): 1018-1029. [30] Chinese Society of Endocrinology. Chinese guidelines for the diagnosis and treatment of hyperuricemia and gout (2019)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂), 2020, 36(1): 1-13. [31] Chinese Medical Doctor Association. Expert consensus on the management of metabolic diseases in Chinese liver transplant recipients(2019)[J]. Chinese Journal of Transplanation(Electronic Edition)(中华移植杂志(电子版)), 2019, 13(3): 187-194. |